Alison M. McCaig
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 13
-
- Lymphoma Diagnosis and Treatment 7
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments 4
-
- Immunodeficiency and Autoimmune Disorders 3
-
- PI3K/AKT/mTOR signaling in cancer 3
- Glycosylation and Glycoproteins Research 2
-
- Advanced Breast Cancer Therapies 2
-
- Acute Lymphoblastic Leukemia research 2
- Co-authors
- Alison M. MichieEmilio CosimoRinako NakagawaMilica VukovicWilliam J. GullickJohn F. SmythSimon P. LangdonJohn G. Gribben
- Partner nations
- United KingdomIndiaCanada
In The Last Decade
Alison M. McCaig
15 papers receiving 649 citations
Peers
Comparison fields: 5 of 57
- Genetics 367
- Pathology and Forensic Medicine 252
- Hematology 134
- Immunology 180
- Oncology 161
Countries citing papers authored by Alison M. McCaig
This map shows the geographic impact of Alison M. McCaig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison M. McCaig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison M. McCaig more than expected).
Fields of papers citing papers by Alison M. McCaig
This network shows the impact of papers produced by Alison M. McCaig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison M. McCaig. The network helps show where Alison M. McCaig may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Alison M. McCaig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2020 | 13 | |
| 4 | 2019 | 180 | |
| 5 | 2018 | 23 | |
| 6 | Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy | 2018 | 1 |
| 7 | 2018 | 24 | |
| 8 | 2017 | 25 | |
| 9 | 2015 | 8 | |
| 10 | 2014 | 56 | |
| 11 | 2013 | 28 | |
| 12 | 2012 | 28 | |
| 13 | 2011 | 59 | |
| 14 | 2009 | 86 | |
| 15 | 2007 | 3 | |
| 16 | Neuregulin expression, function, and signaling in human ovarian cancer cells. | 2002 | 67 |
| 17 | Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. | 2001 | 58 |
About Alison M. McCaig
Alison M. McCaig is a scholar working on Genetics, Pathology and Forensic Medicine and Transplantation, having authored 17 papers that have together received 659 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (7 papers), Chronic Myeloid Leukemia Treatments (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Glycosylation and Glycoproteins Research (2 papers), Advanced Breast Cancer Therapies (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). The work is most often cited by research in Genetics (367 citations), Pathology and Forensic Medicine (252 citations) and Hematology (134 citations). Alison M. McCaig has collaborated with scholars based in United Kingdom, India and Canada. Frequent co-authors include Alison M. Michie, Emilio Cosimo, Rinako Nakagawa, Milica Vukovic, William J. Gullick, John F. Smyth, Simon P. Langdon, John G. Gribben, Chris Fegan and Kristian Brock. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.